The activated NLRP3 inflammasome in IPF-AE may be of potential therapeutic value, and compounds blocking NLRP3-inflammasome activation might be of potential benefit for this fatal condition (53). Here, NLRP3 is linked to idiopathic pulmonary fibrosis.